Motley Fool Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Motley Fool Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$244K	Buy	1,852 +159	+9%	+$21.1K	0.01%	225
2025 Q4	$240K	Buy	1,693 +78	+5%	+$11.3K	0.01%	229
2025 Q3	$227K	Sell	1,615 -1,052	-39%	-$143K	0.01%	229
2025 Q2	$335K	Buy	2,667 +209	+9%	+$24K	0.02%	193
2025 Q1	$272K	Buy	2,458 +209	+9%	+$26.5K	0.02%	203
2024 Q4	$307K	Buy	2,249 +220	+11%	+$27.2K	0.02%	194
2024 Q3	$232K	Sell	2,029 -24	-1%	-$3.29K	0.01%	199
2024 Q2	$288K	Sell	2,053 -14	-0.7%	-$1.92K	0.02%	185
2024 Q1	$285K	Buy	2,067 +197	+11%	+$26.9K	0.02%	201
2023 Q4	$246K	Sell	1,870 -168	-8%	-$19.3K	0.02%	201
2023 Q3	$229K	Buy	+2,038	New	+$215K	0.02%	204
2023 Q1	–	Sell	-1,721	Closed	-$206K	–	172
2022 Q4	$206K	Buy	+1,721	New	+$202K	0.02%	207
2022 Q1	–	Sell	-44	Closed	-$4K	–	284
2021 Q4	$4K	Buy	+44	New	+$4.05K	﹤0.01%	244

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Motley Fool Asset Management's NBIX Position: Q1 2026 in Review

Motley Fool Asset Management increased its Neurocrine Biosciences (NBIX) stake by 9.4% in Q1 2026, buying an estimated $21.1K and bringing the position to 1,852 shares worth $244K. The position accounts for 0.01% of the portfolio, ranked #225.

Motley Fool Asset Management first reported a position in NBIX in Q4 2021 and has held it in 13 quarters since. The position peaked at $335K in Q2 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Motley Fool Asset Management held 1,852 shares of Neurocrine Biosciences worth $244K as of Q1 2026.
Motley Fool Asset Management bought 159 Neurocrine Biosciences shares in Q1 2026, an estimated $21.1K.
Neurocrine Biosciences made up 0.01% of Motley Fool Asset Management's portfolio in Q1 2026, its #225 holding.
Motley Fool Asset Management first reported a position in Neurocrine Biosciences in Q4 2021 and has held it in 13 quarters since.
Motley Fool Asset Management's Neurocrine Biosciences position peaked at $335K in Q2 2025.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Motley Fool Asset Management's 13F filing for Q1 2026, filed 12 May 2026.